Exabis Library:

Welcome to the e-CCO Library!

Search by:

All Congress AbstractsCongress SlidesTools & SkillsVideos & Podcasts

Year: Category:

DOP73: A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn’s Disease and Ulcerative Colitis

Year: 2022

Source: ECCO'22

Authors: Peyrin-Biroulet, L.(1);Arkkila, P.(2);Armuzzi, A.(3);Atreya, R.(4);Danese, S.(5);Ferrante, M.(6);Guardiola, J.(7);Jahnsen, J.(8);Louis, E.(9);Lukáš, M.(10);Reinisch, W.(11);Roblin, X.(12);Smith, P.J.(13);Kwon, T.S.(14);Kim, J.Y.(14);Yoon, S.W.(15);Kim, D.H.(15);

Created: Friday, 11 February 2022, 3:52 PM

DOP73: Antibiotic use differentially affects the risk of antidrug antibody formation during anti-TNFα therapy in Inflammatory Bowel Disease

Year: 2021

Source: ECCO'21 Virtual

Authors: Gorelik, Y.(1);Freilich, S.(2);Gerassy-Vainberg, S.(1);Blatt, A.(1);Pressman, S.(1);Focht, G.(3);Friss, C.(3);Loewenberg Weisband, Y.(4);Greenfeld, S.(5);Kariv, R.(5);Ledderman, N.(6);Iris, D.(7);Kashi, Y.(8);Turner, D.(3);Chowers, Y.(1)

Created: Wednesday, 2 June 2021, 4:12 PM

DOP73: Early biological use in a Belgian, prospective inception cohort of patients with Inflammatory Bowel Disease: the PANTHER cohort

Year: 2024

Source: ECCO'24 Stockholm

Authors: Verstockt, Sare

Created: Tuesday, 30 April 2024, 5:03 PM

DOP73: Efficacy and safety of escalation to tofacitinib 10mg BID for patients with UC following loss of response on 5mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study

Year: 2020

Source: ECCO'20 Vienna

Authors: Alessandro Armuzzi

Created: Tuesday, 23 June 2020, 5:40 PM

Last Modified: Wednesday, 24 June 2020, 12:00 PM by Eloise Lanaud

Year: 2020

Source: ECCO'20 Vienna

Authors: Alessandro Armuzzi

Created: Tuesday, 23 June 2020, 4:58 PM

Files: 1

DOP73: Predicting endoscopic improvement in Ulcerative Colitis using the Ulcerative Colitis Severity Index (UCSI)

Year: 2023

Source: ECCO’23 Copenhagen

Authors: Neeraj Narula

Created: Friday, 14 July 2023, 2:22 PM

DOP73: Predicting endoscopic improvement in Ulcerative Colitis using the Ulcerative Colitis Severity Index (UCSI)

Year: 2023

Source: ECCO’23 Copenhagen

Authors: Wong, E.C.L.(1);Dulai, P.S.(2);Marshall, J.K.(1);Jairath, V.(3);Reinisch, W.(4);Narula, N.(1)*;

Created: Friday, 14 July 2023, 10:43 AM

DOP73: Treatment of perianal fistulas in Crohn’s disease, seton vs. anti-TNF vs. surgical closure following anti-TNF (PISA): a randomised controlled trial

Year: 2019

Source:

ECCO '19 Copenhagen

Authors:

K. Wasmann*¹, E. J. de Groof², M. Stellingwerf¹, G. D'Haens³, C. Ponsioen³, K. Gecse³, M. Dijkgraaf⁴, W. Bemelman², C. Buskens²

Created: Friday, 22 February 2019, 9:41 AM

DOP73: Treatment of perianal fistulas in Crohn’s disease, seton versus anti-TNF versus surgical closure following anti-TNF (PISA): a randomised controlled trial

Year: 2019

Source: ECCO'19 Copenhagen

Authors: Karin Wasmann

Created: Tuesday, 28 May 2019, 3:32 PM

Disease activity Indices, Patient reported outcomes, Quality of life (IBDQ), MDT, 5-ASA, Adalimumab, Anti-TNF agents, Infliximab, Thiopurines (AZA / MP), Perianal disease, Perianal fistulae, Abscess, Perianal disease, Adherence to therapy, Sexuality, Real world data, Patient reported outcomes

Files: 1

DOP74 Effectiveness of dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy: A multicentre international cohort study

Year: 2020

Source:

ECCO'20 Vienna

Authors:

U. Kopylov¹, J. Hanzel², C. Liefferinckx³, D. De Marco⁴, N. Imperatore⁵, N. Plevris⁶, I. Baston-Rey⁷, R. Harris⁸, M. Truyens⁹, V. Domislovic¹⁰, S. Vavricka¹¹, V. Biemans^12,13, S. Myers¹⁴, S. Shaji¹⁴, S. Ben-Horin¹, Y. González Lama¹⁵, C. Gilletta¹⁶, A. Bar-Gil Shitrit¹⁷, Z. Zelinkova¹⁸, R. Weishof¹⁹, D. Storan²⁰, E. Zittan²¹, D. Franchimont³, A. Cremer³, W. Afif⁴, F. Castiglione⁵, C. Lees⁷, M. Barrero de Acosta⁷, T. Lobaton⁹, G. Doherty²⁰, Z. Krznaric¹⁰, M. Pierik¹², F. Hoentjen¹³, D. Drobne²

Created: Thursday, 30 January 2020, 10:12 AM

DOP74: Artificial Intelligence Quantifying Endoscopic Severity of Ulcerative Colitis in Gradation Scale

Year: 2023

Source: ECCO’23 Copenhagen

Authors: Kaoru Takabayashi

Created: Friday, 14 July 2023, 2:22 PM

DOP74: Artificial Intelligence Quantifying Endoscopic Severity of Ulcerative Colitis in Gradation Scale

Year: 2023

Source: ECCO’23 Copenhagen

Authors: Takabayashi, K.(1)*;Kobayashi, T.(2);Matsuoka, K.(3);G Levesque, B.(4);Kawamura, T.(5);Tanaka, K.(5);Kadota, T.(6);Bise, R.(6);Uchida, S.(6);Kanai, T.(7);Ogata, H.(1);

Created: Friday, 14 July 2023, 10:43 AM

DOP74: Comparative effectiveness of vedolizumab and ustekinumab in Crohn’s Disease patients who failed anti-TNF treatment: Interrogating 1019 patients from the UK IBD BioResource

Year: 2022

Source: ECCO'22

Authors: Desoki, R.(1,2);Balendran, K.(1);Kapizioni, C.(1);Shawky, R.(1);Parkes, M.(1);Raine, T.(1);

Created: Friday, 11 February 2022, 3:52 PM

DOP74: Effectiveness of dose escalation in Crohn’s Disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy - A multicenter international cohort study

Year: 2020

Source: ECCO'20 Vienna

Authors: Uri Kopylov

Created: Tuesday, 23 June 2020, 4:58 PM

Files: 1

DOP74: Efficacy of ustekinumab in perianal Crohn’s disease: the BioLAP multi-centre observational study

Year: 2019

Source:

ECCO '19 Copenhagen

Authors:

C. Biron*¹, P. Seksik², M. Nachury³, Y. Bouhnik⁴, A. Amiot⁵, S. Viennot⁶, M. Serrero⁷, M. Fumery⁸, M. Allez⁹, L. Siproudhis¹⁰, A. Buisson¹¹, G. Pineton de Chambrun¹², V. Abitbol¹³, S. Nancey¹⁴, L. Caillo¹⁵, L. Plastaras¹⁶, L. Armengol-Debeir¹⁷, E. Chanteloup¹⁸, M. Simon¹⁹, N. Dib²⁰, S. Rajca²¹, M. Amil²², L. Peyrin-Biroulet²³, L. Vuitton²⁴